keyword
MENU ▼
Read by QxMD icon Read
search

meningococcal b vaccine

keyword
https://www.readbyqxmd.com/read/29152576/meningococcal-antigen-typing-system-mats-based-neisseria-meningitidis-serogroup-b-coverage-prediction-for-the-menb-4c-vaccine-in-the-united-states
#1
Gowrisankar Rajam, Maria Stella, Ellie Kim, Simon Paulos, Giuseppe Boccadifuoco, Laura Serino, George Carlone, Duccio Medini
Neisseria meningitidis is the most common cause of bacterial meningitis in children and young adults worldwide. A 4-component vaccine against N. meningitidis serogroup B (MenB) disease (MenB-4C [Bexsero]; GSK) combining factor H binding protein (fHBP), neisserial heparin binding protein (NHBA), neisserial adhesin A (NadA), and PorA-containing outer membrane vesicles was recently approved for use in the United States and other countries worldwide. Because the public health impact of MenB-4C in the United States is unclear, we used the meningococcal antigen typing system (MATS) to assess the strain coverage in a panel of strains representative of serogroup B (NmB) disease in the United States...
November 2017: MSphere
https://www.readbyqxmd.com/read/29136861/quality-by-design-approach-in-the-development-of-an-ultra-high-performance-liquid-chromatography-method-for-bexsero-meningococcal-group-b-vaccine
#2
Luca Nompari, Serena Orlandini, Benedetta Pasquini, Cristiana Campa, Michele Rovini, Massimo Del Bubba, Sandra Furlanetto
Bexsero is the first approved vaccine for active immunization of individuals from 2 months of age and older to prevent invasive disease caused by Neisseria meningitidis serogroup B. The active components of the vaccine are Neisseria Heparin Binding Antigen, factor H binding protein, Neisseria adhesin A, produced in Escherichia coli cells by recombinant DNA technology, and Outer Membrane Vesicles (expressing Porin A and Porin B), produced by fermentation of Neisseria meningitidis strain NZ98/254. All the Bexsero active components are adsorbed on aluminum hydroxide and the unadsorbed antigens content is a product critical quality attribute...
February 1, 2018: Talanta
https://www.readbyqxmd.com/read/29132992/measuring-the-timeliness-of-childhood-vaccinations-using-cohort-data-and-routine-health-records-to-evaluate-quality-of-immunisation-services
#3
Suzanne Walton, Mario Cortina-Borja, Carol Dezateux, Lucy J Griffiths, Karen Tingay, Ashley Akbari, Amrita Bandyopadhyay, Ronan A Lyons, Helen Bedford
BACKGROUND: To achieve full benefits of vaccination programmes, high uptake and timely receipt of vaccinations are required. OBJECTIVES: To examine uptake and timeliness of infant and pre-school booster vaccines using cohort study data linked to health records. METHODS: We included 1782 children, born between 2000 and 2001, participating in the Millennium Cohort Study and resident in Wales, whose parents gave consent for linkage to National Community Child Health Database records at the age seven year contact...
November 10, 2017: Vaccine
https://www.readbyqxmd.com/read/29128379/active-sms-based-influenza-vaccine-safety-surveillance-in-australian-children
#4
Alexis Pillsbury, Helen Quinn, Patrick Cashman, Alan Leeb, Kristine Macartney
INTRODUCTION: Australia's novel, active surveillance system, AusVaxSafety, monitors the post-market safety of vaccines in near real time. We analysed cumulative surveillance data for children aged 6 months to 4 years who received seasonal influenza vaccine in 2015 and/or 2016 to determine: adverse event following immunisation (AEFI) rates by vaccine brand, age and concomitant vaccine administration. METHODS: Parent/carer reports of AEFI occurring within 3 days of their child receiving an influenza vaccine in sentinel immunisation clinics were solicited by Short Message Service (SMS) and/or email-based survey...
November 8, 2017: Vaccine
https://www.readbyqxmd.com/read/29126310/current-epidemiology-and-trends-in-meningococcal-disease-united-states-1996-2015
#5
Jessica R MacNeil, Amy E Blain, Xin Wang, Amanda C Cohn
Background: In 2005, meningococcal conjugate vaccine (MenACWY) was recommended for routine use among adolescents aged 11-18 years. This report describes the epidemiologic features of meningococcal disease and trends in meningococcal disease incidence following MenACWY introduction in the United States. Methods: Incidence rates and case-fatality ratios by age group and serogroup during 2006-2015 were calculated using data from the National Notifiable Diseases Surveillance System (NNDSS); changes in incidence during this time were evaluated...
November 8, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29116892/lessons-from-the-meningitis-vaccine-project
#6
F Marc LaForce, Mamoudou Djingarey, Simonetta Viviani, Marie-Pierre Preziosi
From 2001 to 2017 the Meningitis Vaccine Project (MVP), a Gates Foundation funded partnership between PATH and the World Health Organization (WHO), successfully developed, tested, licensed, and introduced an affordable new Group A meningococcal conjugate vaccine, MenAfriVac(®), in sub-Saharan Africa. The vaccine was well received, and from 2010 to 2016, over 260 million Africans have received a dose of the vaccine in campaigns largely directed at 1-29-year olds. The public health impact has been dramatic with the elimination of Group A meningococcal infections wherever the vaccine has been used at public health scale...
November 8, 2017: Viral Immunology
https://www.readbyqxmd.com/read/29100708/safety-and-immune-response-after-two-dose-meningococcal-c-conjugate-immunization-in-hiv-infected-children-and-adolescents-in-rio-de-janeiro-brazil
#7
Ana Cristina C Frota, Bianca Ferreira, Lee H Harrison, Gisele S Pereira, Wania Pereira-Manfro, Elizabeth S Machado, Ricardo Hugo de Oliveira, Thalita F Abreu, Lucimar G Milagres, Cristina B Hofer
We aimed to evaluate immunogenicity and adverse events (AEs) after a booster dose of Meningococcal C conjugated (MCC) vaccine in HIV-infected children and adolescents, who had a previous low seroconversion rate after priming with MCC, at a reference HIV-care center in Rio de Janeiro. METHODS: 2-18 years old HIV-infected subjects with CD4+ T-lymphocyte cell (CD4) ≥15%, without active infection or antibiotic use, were enrolled to receive 2 doses of conjugated meningococcal C oligosaccharide-CRM197 12-18 months apart...
October 31, 2017: Vaccine
https://www.readbyqxmd.com/read/29092704/epidemiology-of-invasive-meningococcal-b-disease-in-australia-1999-2015-priority-populations-for-vaccination
#8
Brett N Archer, Clayton K Chiu, Sanjay H Jayasinghe, Peter C Richmond, Jodie McVernon, Monica M Lahra, Ross M Andrews, Peter B McIntyre
OBJECTIVES: To describe trends in the age-specific incidence of serogroup B invasive meningococcal disease (IMD) in Australia, 1999-2015. DESIGN, SETTING, PARTICIPANTS: Analysis in February 2017 of de-identified notification data from the Australian National Notifiable Diseases Surveillance System of all notifications of IMD in Australia with a recorded diagnosis date during 1999-2015.Major outcomes: IMD notification rates in Australia, 1999-2015, by age, serogroup, Indigenous status, and region...
November 6, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/29065137/differences-in-the-population-structure-of-neisseria-meningitidis-in-two-australian-states-victoria-and-western-australia
#9
Shakeel Mowlaboccus, Christopher A Mullally, Peter C Richmond, Benjamin P Howden, Kerrie Stevens, David J Speers, Anthony D Keil, Ottar N Bjørnstad, Timothy T Perkins, Charlene M Kahler
Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD). A recombinant vaccine called Bexsero® incorporates four subcapsular antigens (fHbp, NHBA, NadA and PorA) which are used to assign a Bexsero® antigen sequence type (BAST) to each meningococcal strain. The vaccine elicits an immune response against combinations of variants of these antigens which have been grouped into specific BAST profiles that have been shown to have different distributions within geographical locations thus potentially affecting the efficacy of the vaccine...
2017: PloS One
https://www.readbyqxmd.com/read/29064356/expansion-of-vaccination-services-and-strengthening-vaccine-preventable-diseases-surveillance-in-haiti-2010-2016
#10
Rania A Tohme, Jeannot Francois, Kathleen F Cavallaro, Gilson Paluku, Idrissa Yalcouye, Ernsley Jackson, Tracie Wright, Paul Adrien, Mark A Katz, Terri B Hyde, Pape Faye, Francine Kimanuka, Vance Dietz, John Vertefeuille, David Lowrance, Benjamin Dahl, Roopal Patel
Following the 2010 earthquake, Haiti was at heightened risk for vaccine-preventable diseases (VPDs) outbreaks due to the exacerbation of long-standing gaps in the vaccination program and subsequent risk of VPD importation from other countries. Therefore, partners supported the Haitian Ministry of Health and Population to improve vaccination services and VPD surveillance. During 2010-2016, three polio, measles, and rubella vaccination campaigns were implemented, achieving a coverage > 90% among children and maintaining Haiti free of those VPDs...
October 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29048985/commentary-impact-of-meningococcal-group-b-omv-vaccines-beyond-their-brief
#11
Helen Petousis-Harris
Meningococcal group B outer membrane vesicle vaccines have been used widely in Cuba, New Zealand, and Brazil. They are immunogenic and initially assessed largely by their ability to induce serum bactericidal activity. Measures of efficacy indicate good protection against homologous strains in older children and adults. Effectiveness appears broader than predicted by immunogenicity and efficacy studies. The recent discovery that meningococcal group B OMVs may protect against the related Neisseria species N.gonorrhoeae suggests more to these interesting antigen collections than meets the eye...
October 19, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29038320/persistence-of-immunity-after-vaccination-with-a-capsular-group-b-meningococcal-vaccine-in-3-different-toddler-schedules
#12
RANDOMIZED CONTROLLED TRIAL
Manish Sadarangani, Tim Sell, Mildred A Iro, Matthew D Snape, Merryn Voysey, Adam Finn, Paul T Heath, Gianni Bona, Susanna Esposito, Javier Diez-Domingo, Roman Prymula, Adefowope Odueyungbo, Daniela Toneatto, Andrew J Pollard
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12-24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12-24 months of age received a booster at 4 years of age...
October 16, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/28992986/pros-and-cons-of-vaccination-against-disease-caused-by-serogroup-b-meningococcal-disease
#13
REVIEW
Miguel Delgado Rodríguez, Ángela Domínguez García
A vaccine has recently been approved in the EU against meningococcal serogroup B, the main cause of meningococcal disease. There is a fierce debate about the decision regarding a universal vaccination in infants older than 2 months, as recommended by the majority of scientific societies. In western Europe the only country to have included the universal vaccination is the United Kingdom, with a lower incidence of the disease than Ireland. Other countries have also adopted it, such as the Czech Republic, Cuba and certain regions of Italy...
October 7, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28968661/meningococcal-carriage-following-a-university-serogroup-b-meningococcal-disease-outbreak-and-vaccination-campaign-with-menb-4c-and-menb-fhbp-oregon-2015-2016
#14
Lucy A McNamara, Jennifer Dolan Thomas, Jessica MacNeil, How Yi Chang, Michael Day, Emily Fisher, Stacey Martin, Tasha Poissant, Susanna E Schmink, Evelene Steward-Clark, Laurel Thompson Jenkins, Xin Wang, Anna Acosta
Background: Limited data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and MenB-4C on meningococcal carriage and herd protection. We therefore assessed meningococcal carriage following a MenB vaccination campaign in response to a university serogroup B meningococcal disease outbreak in 2015. Methods: A convenience sample of students recommended for vaccination provided oropharyngeal swabs and completed questionnaires during four carriage surveys over 11 months...
August 26, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28965718/efficacy-and-immunogenicity-of-a-vi-tetanus-toxoid-conjugate-vaccine-in-the-prevention-of-typhoid-fever-using-a-controlled-human-infection-model-of-salmonella-typhi-a-randomised-controlled-phase-2b-trial
#15
Celina Jin, Malick M Gibani, Maria Moore, Helene B Juel, Elizabeth Jones, James Meiring, Victoria Harris, Jonathan Gardner, Anna Nebykova, Simon A Kerridge, Jennifer Hill, Helena Thomaides-Brears, Christoph J Blohmke, Ly-Mee Yu, Brian Angus, Andrew J Pollard
BACKGROUND: Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20 million infections and 200 000 deaths each year in resource poor regions of the world. Capsular Vi-polysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogenic and can be used from infancy but there are no efficacy data for the leading candidate vaccine being considered for widespread use. To address this knowledge gap, we assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established human infection model of S Typhi...
September 28, 2017: Lancet
https://www.readbyqxmd.com/read/28956803/infant-immunization-coverage-in-italy-2000-2016
#16
Carlo Signorelli, Anna Odone, Paola Cella, Stefania Iannazzo, Fortunato D'Ancona, Raniero Guerra
BACKGROUND: In Italy, national-level immunization polices are included in the National Immunization Prevention Plan (PNPV), whose latest edition - 2017-2019 PNPV - was finally approved in February 2017. Coverage rates are a key measure of immunization system performance; it can inform and support national and regional polices' implementation monitoring, as well as measure the impact of interventions aimed at increasing vaccine uptake. METHODS: We collected, analysed and critically interpreted 2000-2016 Italian national infant immunization coverage trends, by different vaccine, target population, and by Region...
July 2017: Annali Dell'Istituto Superiore di Sanità
https://www.readbyqxmd.com/read/28931535/risk-of-hospitalisation-with-fever-following-menb-vaccination-self-controlled-case-series-analysis
#17
Heather Murdoch, Lynn Wallace, Jennifer Bishop, Chris Robertson, J Claire Cameron
OBJECTIVE: To investigate a possible association between fever admissions and 4 component Meningococcal B (4CMenB). DESIGN: 4CMenB is given at 8 and 16 weeks in the first year of life. Self-controlled case series using linked routinely collected healthcare data, where the risk period was the 3 days immediately following receipt of a vaccine dose. PATIENTS: Children aged under 1 year in Scotland preintroduction and postintroduction of 4CMenB vaccine (pre-September 2014 to August 2015 and post-September 2015 to June 2016)...
October 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28931534/the-yin-and-yang-of-fever-after-meningococcal-b-vaccination
#18
EDITORIAL
Shamez N Ladhani, Andrew Riordan
No abstract text is available yet for this article.
October 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28931058/molecular-characterization-of-neisseria-meningitidis-isolates-recovered-from-11-19-year-old-meningococcal-carriers-in-salvador-brazil
#19
Ana Rafaela Silva Simões Moura, Cécilia Batmalle Kretz, Italo Eustáquio Ferreira, Amélia Maria Pithon Borges Nunes, José Cássio de Moraes, Mitermayer Galvão Reis, Alan John Alexander McBride, Xin Wang, Leila Carvalho Campos
Characterization of meningococci isolated from the pharynx is essential towards understanding the dynamics of meningococcal carriage and disease. Meningococcal isolates, collected from adolescents resident in Salvador, Brazil during 2014, were characterized by multilocus sequence typing, genotyping or whole-genome sequencing. Most were nongroupable (61.0%), followed by genogroups B (11.9%) and Y (8.5%). We identified 34 different sequence types (STs), eight were new STs, distributed among 14 clonal complexes (cc), cc1136 represented 20...
2017: PloS One
https://www.readbyqxmd.com/read/28903515/update-from-the-advisory-committee-on-immunization-practices
#20
Sean T O'Leary, Yvonne A Maldonado, Carrie L Byington
The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group has 15 voting members, and each member's term is 4 years. ACIP members and Centers for Disease Control and Prevention (CDC) staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (C...
September 1, 2017: Journal of the Pediatric Infectious Diseases Society
keyword
keyword
61786
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"